When science goes viral: The research response during three months of the COVID-19 outbreak.
Academia
Bibliometric analysis
COVID-19
Emerging infectious disease
SARS-CoV-2
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
10
05
2020
revised:
18
06
2020
accepted:
21
06
2020
pubmed:
1
7
2020
medline:
8
9
2020
entrez:
1
7
2020
Statut:
ppublish
Résumé
Here we present the results of a bibliometric survey of peer-reviewed and pre-print papers published in the English language on issues related to COVID-19 within the first three months since a cluster of a severe acute respiratory disease of unknown etiology was officially confirmed by the Chinese Center for Disease Control and Prevention on 31 December 2019. A systematic search using PubMed/Medline and Scopus databases and preprint servers was performed. The articles were classified according to their type, subject and country of origin. Up to 31 March 2020, a total of 2062 papers published in 578 peer-reviewed journals and 1425 preprints posted mostly on medRxiv (55.4 %), were identified. The mean number of published journal papers and preprints per day in the considered period was 27 and 12, respectively, and reached a maximum of 51 and 46 per day in March, respectively. The identified articles, journal papers and preprints, mostly covered the epidemiology of COVID-19 (35.7 %), clinical aspects of infection (21.0 %), preventative measures (12.8 %), treatment options (12.5 %), diagnostics (12.2 %), mathematical modeling of disease transmission and mitigation (9.6 %), and molecular biology and pathogenesis of SARS-CoV-2 (8.7 %). The majority of the journal papers were commentaries (38.5 %), reviews (33.6 %) and original research (21.3 %), while preprints predominantly presented original results (89.8 %). Chinese scientists contributed the highest share of original research and were responsible for 32.9 % journal papers and 43.9 % preprints published in the considered period. A high number of contributions was also seen from the United States, the United Kingdom, and Italy. The benefits and potential risks of such a massive publication output are discussed. The scientific response seen during the first 3 months of the COVID-19 outbreak is a demonstration of the capabilities of modern science to react rapidly to emerging global health threats by providing and discussing the essential information for understanding the etiological factor, its spread, preventative measures, and mitigation strategies.
Identifiants
pubmed: 32603887
pii: S0753-3322(20)30644-2
doi: 10.1016/j.biopha.2020.110451
pmc: PMC7309857
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110451Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.
Références
Nature. 2020 Mar;579(7797):29
pubmed: 32127711
Int J Surg. 2020 May;77:217
pubmed: 32305321
Lancet Infect Dis. 2020 Jun;20(6):657-658
pubmed: 32213330
J Med Virol. 2020 Jun;92(6):540-545
pubmed: 32108352
Lancet. 2020 Mar 28;395(10229):1063-1077
pubmed: 32145185
Euro Surveill. 2020 Jan;25(4):
pubmed: 32019669
Lancet. 2020 Feb 22;395(10224):e39
pubmed: 32035510
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
J Med Virol. 2020 Jun;92(6):556-563
pubmed: 32104907
Future Virol. 2019 Apr;14(4):237-246
pubmed: 32201499
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
N Engl J Med. 2004 Apr 22;350(17):1740-5
pubmed: 15103000
Lancet Respir Med. 2020 Jun;8(6):539-541
pubmed: 32304640
Lancet Infect Dis. 2020 Apr;20(4):408-409
pubmed: 32085849
N Engl J Med. 2020 May 7;382(19):1832-1842
pubmed: 32441897
N Engl J Med. 2020 May 7;382(19):1861-1862
pubmed: 32220206
Lancet. 2020 Feb 22;395(10224):537
pubmed: 32087777
Med Mal Infect. 2020 May;50(3):243-251
pubmed: 31727466
Lancet Infect Dis. 2020 Jun;20(6):655-656
pubmed: 32171389
PLoS Biol. 2017 Nov 16;15(11):e2003995
pubmed: 29145518
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Microbiology (Reading). 2019 May;165(5):489-491
pubmed: 30938669
JAMA. 2018 Feb 6;319(5):443-444
pubmed: 29192310
Science. 2020 Mar 20;367(6484):1313
pubmed: 32193314
Lancet Digit Health. 2020 Apr;2(4):e201-e208
pubmed: 32309796
Arch Virol. 2020 Jul;165(7):1517-1526
pubmed: 32322993
Biosci Trends. 2020 Mar 16;14(1):69-71
pubmed: 31996494
Nat Rev Drug Discov. 2020 May;19(5):305-306
pubmed: 32273591
Nature. 2020 Feb;578(7793):7
pubmed: 32020126
Sci China Life Sci. 2020 May;63(5):774-776
pubmed: 32124179
World J Pediatr. 2020 Jun;16(3):251-259
pubmed: 32193831
J Travel Med. 2020 Mar 13;27(2):
pubmed: 31943059
Rev Panam Salud Publica. 2020 Mar 20;44:e40
pubmed: 32256547
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Acta Biomed. 2020 Mar 19;91(1):157-160
pubmed: 32191675
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2019 Mar 2;393(10174):936-948
pubmed: 30777297
Infect Dis Poverty. 2020 Feb 28;9(1):24
pubmed: 32111262
N Engl J Med. 2020 Mar 26;382(13):1278-1280
pubmed: 32069388
J Med Microbiol. 2003 Aug;52(Pt 8):609-613
pubmed: 12867552
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Med Anthropol. 2020 Jul;39(5):367-370
pubmed: 32212930
BMC Med. 2020 Mar 18;18(1):89
pubmed: 32188445
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Int Immunopharmacol. 2020 Sep;86:106711
pubmed: 32585609
Science. 2003 May 30;300(5624):1399-404
pubmed: 12730501
Mayo Clin Proc. 2003 Jul;78(7):882-90
pubmed: 12839084
Am J Gastroenterol. 2020 May;115(5):790
pubmed: 32205644
J Clin Med. 2020 Feb 07;9(2):
pubmed: 32046137
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204